Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rejuvesol in Pediatric Cardiac Surgery
NCT02485366Phase 4Withdrawn
- Sponsor
- Duke University
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- Injectable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rejuvesol in congenital heart defects (CHD), sponsored by Duke University. Planned start Jun 2020; status: withdrawn.
02
Drugs
rejuvesol
03
Conditions
congenital heart defects (CHD)
Beyond the preview
Go deeper on NCT02485366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485366.